Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks provides biological research and development services and tools to government and commercial customers. Its two segments are cell engineering and biosecurity. Cell engineering services help customers discover, optimize and manufacture biotechnology products, including medicines, vaccines, agricultural products, chemicals, enzymes and proteins. Ginkgo also provides cell engineering tools such as automation systems, data-generation services, AI models and licenses to biological assets. It does not make end products. Biosecurity services primarily serve government customers. Canopy provides biomonitoring programs that collect and analyze genomic data from strategic locations, while Horizon is a platform for detecting and monitoring biothreats. Ginkgo makes money by charging fees for its services, tools, automation systems and support, with cell engineering programs typically priced through fixed fees and sometimes technical milestone payments. Its headquarters are in Boston.
Ginkgo Bioworks (NYSE:DNA) reported a strategic shift toward commercializing autonomous lab hardware and cloud services during its Q3 2026 earnings call. Key points include selling hardware to biopharma partners, restructuring to reduce cash burn, and AI-driven demand for lab data. The company ended the quarter with $285M in cash and no debt. Novo Nordisk is a notable partner.
Ginkgo Bioworks (DNA) reported Q3 2026 earnings, showing a 44% improvement in net loss from continuing operations to $41M and a 58% improvement in adjusted EBITDA to -$22M. Revenue was $28M, down 6% YoY. The company highlighted cost-cutting efforts, reduced cash burn, and investments in autonomous labs. They ended the quarter with $285M in cash and reaffirmed full-year cash burn guidance of $125M-$150M.
Ginkgo Bioworks reaffirmed its 2026 cash burn guidance of $125M-$150M and announced its first pharma autonomous lab sale to Novo Nordisk. The news was shared during the company's Q3 2026 earnings call. Novo Nordisk trades under the ticker DNA on the NYSE.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning DNA (Ginkgo Bioworks Holdings, Inc.). Coverage has been balanced: 2 bullish, 0 neutral, and 2 bearish.
Recent DNA coverage spans insider activity, earnings and financial news.
In the last 30 days, DNA insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($889K). The most active reporter was Coen Steven P., See remarks, with 1 filing.
The new hardware offering and pharma partnership could drive higher recurring revenue and improve margins, supporting a potential stock upside.
Improved loss and stable guidance may support modest upside.
The guidance reaffirmation and new sale suggest higher near‑term cash consumption, which may pressure the stock.
The earnings miss and loss may weigh on the stock.
The insider sale may signal slight negative sentiment.
AlphAI scores every news story that mentions DNA with an AI model for sentiment and relevance, and aggregates insider trades from Ginkgo Bioworks Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ginkgo Bioworks (NYSE:DNA) reported a strategic shift toward commercializing autonomous lab hardware and cloud services during its Q3 2026 earnings call. Key points include selling hardware to biopharma partners, restructuring to reduce cash burn, and AI-driven demand for lab data. The company ended the quarter with $285M in cash and no debt. Novo Nordisk is a notable partner.
Ginkgo Bioworks (DNA) reported Q3 2026 earnings, showing a 44% improvement in net loss from continuing operations to $41M and a 58% improvement in adjusted EBITDA to -$22M. Revenue was $28M, down 6% YoY. The company highlighted cost-cutting efforts, reduced cash burn, and investments in autonomous labs. They ended the quarter with $285M in cash and reaffirmed full-year cash burn guidance of $125M-$150M.
Ginkgo Bioworks reaffirmed its 2026 cash burn guidance of $125M-$150M and announced its first pharma autonomous lab sale to Novo Nordisk. The news was shared during the company's Q3 2026 earnings call. Novo Nordisk trades under the ticker DNA on the NYSE.
Ginkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo Ginkgo provides an update on its third quarter financial results and the growth of its two prevailing offerings built on one autonomous lab platform:
Canton Barry sold 22,369 indirectly-held shares of Ginkgo Bioworks Holdings, Inc. (DNA) at $10.14 ($0.23M total) on 2026-10-19.
Canton Barry sold 18,803 shares of Ginkgo Bioworks Holdings, Inc. (DNA) at $10.14 ($0.19M total) on 2026-10-19.
Shetty Reshma P. (See remarks) sold 18,803 indirectly-held shares of Ginkgo Bioworks Holdings, Inc. (DNA) at $10.14 ($0.19M total) on 2026-10-19.
Shetty Reshma P. (See remarks) sold 22,369 shares of Ginkgo Bioworks Holdings, Inc. (DNA) at $10.14 ($0.23M total) on 2026-10-19.
Kelly Jason R (See remarks) sold 45,682 shares of Ginkgo Bioworks Holdings, Inc. (DNA) at $10.14 ($0.46M total) on 2026-10-19.
Ginkgo Bioworks (NYSE:DNA) will provide access to its Boston lab for the NSF X-Labs program, a $1.5B initiative. The company will offer cloud lab time and protein testing services to researchers, using its robotic infrastructure and software. Ginkgo already collaborates with NSF through another program.
